Atiprimod [CAS 123018-47-3]

Atiprimod (Azaspirane) is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML) [1][2][3][4][5][6].

[123018-47-3]

C22H44N2

336.6

CCN(CCCN1CCC2(CCC(CCC)(CC2)CCC)C1)CC

Apoptosis; Atg8/LC3; Autophagy; Bcl-2 Family; Caspase; JAK; NF-κB; p62; PARP; PERK; Reactive Oxygen Species (ROS) ; STAT

Room temperature